Marketing Pharmaceutical Safety 
The Dermatology Digest
NOVEMBER 30, 2024
Several new therapies are coming down the pike for the treatment of lichen planus, a chronic inflammatory condition that affects an estimated 1% to 2% of the global population, according to a new report from Research and Markets. Incyte is investigating the efficacy and safety of ruxolitinib cream in cutaneous lichen planus.
The Dermatology Digest
FEBRUARY 8, 2024
Jashin Wu, MD, founder and CEO of the Dermatology Research and Education Foundation in San Diego, CA, says that more psoriasis patients will see improvements in their condition due to the influx of new agents and biosimilars on the market. Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Dermatology Digest
FEBRUARY 16, 2024
The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) and Novartis Pharmaceuticals). Japan is the first country to approve dupilumab for CSU. This study met the primary and all key secondary endpoints.
The Dermatology Digest
MAY 15, 2024
Verrica Pharmaceuticals Inc. has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. seeking Food and Drug Administration approval for the use of YCANTH for the treatment of common warts, but may also be utilized by Verrica to seek future marketing authorizations in territories outside the U.S.
The Dermatology Digest
JULY 22, 2024
Launching Uzpruvo at the earliest opportunity in Europe’s largest pharmaceutical markets, promotes access by creating competition,” says STADA CEO Peter Goldschmidt in a news release. We are delighted at the launch of Uzpruvo in Europe and to be first-to-market,” adds Robert Wessman, Chief Executive Officer of Alvotech.
The Dermatology Digest
FEBRUARY 27, 2024
While both low-concentration and high-concentration strength biosimilars of Humira are marketed in the U.S. We strongly believe that biosimilars are important in addressing inflationary pressures in the healthcare system across all markets, especially in the U.S. where biologics represent well over 40% of all pharmaceutical spending.
The Beauty Brains
MARCH 4, 2019
They also have advice from a body called the scientific committee for cosmetic safety or SCCS, which is composed largely of academics with an interest in medicine and general science. This is a simply enormous database of every cosmetic formulation on the market along with its pack copy. Smaller producers? Not so much.
Expert insights. Personalized for you.
36 
Let's personalize your content